Acrobiosystems for English
icon_bulk_orderAnfrage Sammelbestellung/Schnellbestellung
user
  1. Übersicht
  2. Mein Profil
  3. Meine Adresse
  4. Meine Bestellungen
  5. Acro-Mitgliedschaft
Login Registrieren
Promotion
Recombinant Proteins ClearClear history
Recombinant Proteins CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP IL-2 Hot |Omicron specific antibody  |Claudin 18.2 |Cadherin-17 
0
Es befinden sich keine Waren im Warenkorb !
Mein Warenkorb|Check Out
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Start > EphA2

EphA2

Brief Information

Name:Ephrin type-A receptor 2
Target Synonym:EC:2.7.10.1,Epithelial Cell Receptor Protein Tyrosine Kinase,Ephrin type-A receptor 2,Epithelial cell kinase,EPHA2,EPH Receptor A2,Tyrosine-Protein Kinase Receptor ECK,ECK,Soluble EPHA2 Variant 1,EC 2.7.10.1,CTRCT6,ARCC2,CTPP1,CTPA,Receptor, EphA2,EC 2.7.10
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Approved

Product ListCompare or Buy

Product> Filter Results
Nach Produktstatus:
Nach Produktkategorie :
Nach Arten:
Nach Markierungen:
Nach Konjugaten:
Kat. Nr. Arten Produktbeschreibung Struktur Reinheit Merkmal
EP2-H82E4 Human Biotinylated Human EphA2 Protein, His,Avitag™ (MALS verified)
EP2-H82E4-structure
EP2-H82E4-sds
ACRO Quality

Part of Bioactivity data

EP2-H82E4-MALS-HPLC
EphA2 MALS images

The purity of Biotinylated Human EphA2 Protein, His,Avitag (Cat. No. EP2-H82E4) is more than 95% and the molecular weight of this protein is around 55-70 kDa verified by SEC-MALS.

EP2-H82E4-ELISA
EphA2 ELISA

Immobilized Biotinylated Human EphA2 Protein, His,Avitag (Cat. No. EP2-H82E4) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Human Ephrin-A1, Fc Tag (Cat. No. EF1-H5251) with a linear range of 0.1-1 ng/mL (QC tested).

Protocol

Synonym Name

EphA2

Background

Receptor tyrosine kinase which binds promiscuously membrane-bound ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Activated by the ligand ephrin-A1/EFNA1 regulates migration, integrin-mediated adhesion, proliferation and differentiation of cells. Regulates cell adhesion and differentiation through DSG1/desmoglein-1 and inhibition of the ERK1/ERK2 (MAPK3/MAPK1, respectively) signaling pathway. Engaged by the ligand ephrin-A5/EFNA5 may regulate lens fiber cells shape and interactions and be important for lens transparency development and maintenance. With ephrin-A2/EFNA2 may play a role in bone remodeling through regulation of osteoclastogenesis and osteoblastogenesis.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Dasatinib Hydrate BMS-354825; XS-004; NSC-732517 Approved Bristol-Myers Squibb Company Dasynoc, Spricel, Sprycel, Spraysel, 施达赛 United States Leukemia, Myelogenous, Chronic; Precursor Cell Lymphoblastic Leukemia-Lymphoma Bristol-Myers Squibb Company 2006-06-28 Gliosarcoma; Intraocular Lymphoma; Neoplasms, Gonadal Tissue; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Carcinoma, Squamous Cell; Lymphoma; Giant Cell Tumor of Bone; Gastrointestinal Stromal Tumors; Peritoneal Neoplasms; Primary Myelofibrosis; Astrocytoma; Waldenstrom Macroglobulinemia; Leukemia, Myeloid, Chronic-Phase; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Neurofibrosarcoma; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Sarcoma; Cholangiocarcinoma; Sarcoma, Ewing; Prostatic Neoplasms; Breast Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Leukemia, Large Granular Lymphocytic; Leukemia, T-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Adenocarcinoma; Mastocytosis; Mycosis Fungoides; Tongue Neoplasms; Melanoma; Heart Arrest; Neoplasm Metastasis; Brain Neoplasms; Lymphoma, T-Cell, Cutaneous; Burkitt Lymphoma; Hemangiopericytoma; Uterine Neoplasms; Fallopian Tube Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell; S Details
Regorafenib DAST; BAY-73-4506 Approved Bayer AG Stivarga, Resihance United States Colorectal Neoplasms Bayer Healthcare Pharmaceuticals Inc 2012-09-27 Esophageal adenocarcinoma; Osteosarcoma; Sarcoma, Ewing; Bile Duct Neoplasms; Peritoneal Neoplasms; Bone Neoplasms; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Fallopian Tube Neoplasms; Lung Neoplasms; Thyroid Neoplasms; Sarcoma; Leukemia, Myeloid, Acute; Thymoma; Melanoma; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular; Adenocarcinoma; Somatostatinoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Solid tumours; Liver Neoplasms; Carcinoid Tumor; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Islet Cell; Insulinoma; Hemangiosarcoma; Rectal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Pancreatic Neoplasms; Colonic Neoplasms; Neoplasms; Glioblastoma; Carcinoma, Transitional Cell; Glucagonoma; Carcinoma, Adenoid Cystic; Adenoma; Gastrinoma Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
18F-Dasatinib 18F-SKI-249380; [18F]-Fluoro-BMS-354825; [18F]Dasatinib; [18F]SKI-249380; [18F]Fluoro-BMS-354825 Phase 1 Clinical Memorial Sloan Kettering Cancer Center Bone Marrow Neoplasms; Carcinoma; Neoplasms; Sarcoma; Diagnostic agents; Lymphoma; Melanoma Details
siRNA-EphA2-DOPC Phase 1 Clinical The University Of Texas MD Anderson Cancer Center Solid tumours; Ovarian Neoplasms; Pancreatic Neoplasms Details
Autologous Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13R alpha2 CAR (E-SYNC) T Cells therapy(California Institute For Regenerative Medicine) Phase 1 Clinical California Institute For Regenerative Medicine, National Cancer Institute Glioblastoma Details
BT-5528 BT-5528; BT5528 Phase 2 Clinical Bicycle Therapeutics Ovarian Neoplasms; Head and Neck Neoplasms; Carcinoma; Triple Negative Breast Neoplasms; Carcinoma, Non-Small-Cell Lung Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Email
E-Mail
order@acrobiosystems.com
Fax
Fax
+1 888-377-6111
Address
Address
Lichtstrasse 35,4056 Basel, Switzerland
linkedin twitter facebook youtube

Nachricht schicken

Copyright © 2017 ACROBiosystems. All Rights Reserved
Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap